While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this ...
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the ...
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously ...
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...
In life sciences manufacturing, inspections by the FDA, state regulators or other agencies are part of the job. But too often ...
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing ...
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC ...
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis ...
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging ...
The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results